SCIENTIFIC PUBLICATIONS
Recent Publications
- Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting. Tameris M, Rozot V, Imbratta C, Geldenhuys H, Mendelsohn SC, Kany Luabeya AK, Shenje J, Tredoux N, Fisher M, Mulenga H, Bilek N, Young C, Veldsman A, Botes N, Thole J, Fritzell B, Mukherjee R, Jelsbak IM, Rodriguez E, Puentes E, Doce J, Marinova D, Gonzalo-Asensio J, Aguilo N, Martin C, Scriba TJ, Hatherill M; MTBVAC 202 study team. EBioMedicine. 2025 Apr;114:105628. doi: 10.1016/j.ebiom.2025.105628. Epub 2025 Mar 17.
- A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Cavaleri, M, Alves de Sousa CM, Hacker A, Higgs ES, Lumpkin MM, Maia CS, Mathur R, Fimbo AM, Reis A, Shin KS, Vaugh DW, Zhang W, Moorthy, V. Lancet Glob Health. 2025 Apr.;13(4)
- Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice. Gobat N, Slack C, Hannah S, Salzwedel J, Bladon G, Burgos JG, Purvis B, Molony-Oates B, Siegfried N, Cheah PY, Conway M, Kamuya D, Davies A, Johnson T, Tholanah M, Mugamba S, Mutengu NL, Machingaidze S, Schwartz L, Rägo L, von Harbou K. Lancet Glob Health. 2025 Apr;13:e716-31
- Trained immunity-based mucosal immunotherapies for the prevention of respiratory infections. Minute L, Montalbán-Hernández K, Bravo-Robles L, Conejero L, Iborra S, Del Fresno C. Trends Immunol. 2025 Apr;46(4):270-283. doi: 10.1016/j.it.2025.02.012. Epub 2025 Mar 19.
- Isolation and characterization of a protective monoclonal antibody targeting outer membrane protein (OmpA) against tuberculosis. Li H, Ji J, Qu M, Ma X, Zuo Y, Tang M, Zeng L, Li H. Microbiol Spectr. 2025 Apr;13(4):e0294224. doi: 10.1128/spectrum.02942-24. Epub 2025 Feb 18.
- A temperature-responsive PLA-based nanosponge as a novel nanoadjuvant and efficient delivery carrier of Ag85B for effective vaccine against Mycobacterium tuberculosis. Yun JS, Kim SM, Lee JS, Jeong SH, Oh H, Son P, Kim S, Lee YR, Shin E, Ha SJ, Jung YW, Kim D, Jeong HS, Choi WI. Cell Commun Signal. 2025 Apr 1;23(1):159. doi: 10.1186/s12964-025-02105-2.
- Synthesis of an Adjuvant-Free Single Polypeptide-Based Tuberculosis Subunit Vaccine that Elicits In Vivo Immunogenicity in Rats. Phogat S, Yadav J, Chaudhary D, Jaiwal R, Jaiwal PK. Mol Biotechnol. 2025 Apr 2. doi: 10.1007/s12033-025-01431-7. Epub ahead of print.
- BCG induced innate immune response heterogeneity and susceptibility to pediatric tuberculosis. Anterasian C, Gela A, Mwambene TD, Shah JA, Ivie J, Dill-McFarland KA, Hanekom WA, Kiritsy MC, Sassetti CM, Musvosvi M, Hatherill M, Scriba TJ, Hawn TR. J Immunol. 2025 Apr 2:vkae062. doi: 10.1093/jimmun/vkae062. Epub ahead of print.
- Factors influencing vaccine hesitancy toward non-covid vaccines in South Asia: a systematic review. Stuetzle SCW, Willis M, Barnowska EJ, Bonkass AK, Fastenau A. BMC Public Health. 2025 Apr 2;25(1):1246. doi: 10.1186/s12889-025-22462-4.
- Deconvoluting the interplay of innate and adaptive immunity in BCG-induced nonspecific and TB-specific host resistance. Hilligan KL, Darrah PA, Seder RA, Sher A. J Exp Med. 2025 Apr 7;222(4):e20240496. doi: 10.1084/jem.20240496. Epub 2025 Mar 18.
- Lyophilization Strategy Enhances the Thermostability and Field-Based Stability of Conjugated and Comixed Subunit Liposomal Adjuvant-containing Tuberculosis Vaccine Formulation (ID93 + GLA-LSQ). Adeagbo BA, Alao M, Orherhe O, Akinloye A, Boukes G, Willenburg E, Fenner C, Bolaji OO, Fox CB. Mol Pharm. 2025 Apr 7;22(4):2306-2315. doi: 10.1021/acs.molpharmaceut.5c00150. Epub 2025 Mar 19.
- Noncanonical T cell responses are associated with protection from tuberculosis in mice and humans. Proulx MK, Wiggins CD, Reames CJ, Wu C, Kiritsy MC, Xu P, Gallant JC, Grace PS, Fenderson BA, Smith CM, Lindestam Arlehamn CS, Alter G, Lauffenburger DA, Sassetti CM. J Exp Med. 2025 Apr 7. doi: 10.1084/jem.20241760. Epub ahead of print.
- Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes. Simonson AW, Zeppa JJ, Bucsan AN, Chao MC, Pokkali S, Hopkins F, Chase MR, Vickers AJ, Sutton MS, Winchell CG, Myers AJ, Ameel CL, Kelly RJ, Krouse B, Hood LE, Li J, Lehman CC, Kamath M, Tomko J, Rodgers MA, Donlan R, Chishti H, Borish HJ, Klein E, Scanga CA, Fortune SM, Lin PL, Maiello P, Roederer M, Darrah PA, Seder RA, Flynn JL. J Exp Med. 2025 Apr 7;222(4):e20241571. doi: 10.1084/jem.20241571. Epub 2025 Feb 6.
- Early secretory antigen target of 6-kDa of Mycobacterium tuberculosis inhibits macrophage apoptosis and host defense via TLR2. Zhang L, Fang F, Liu D, Xia G, Feng T, Lv J, Qi J, Li T, Liu H, Xu T, Wu F, Song C, Li W, Wang X, Chang X, Wang H, Wang T, Qian Z. Respir Res. 2025 Apr 9;26(1):131. doi: 10.1186/s12931-025-03210-z.
- New Advances in the Development and Design of Mycobacterium tuberculosis Vaccines: Construction and Validation of Multi-Epitope Vaccines for Tuberculosis Prevention. Barazani O, Erdos T, Chowdhury R, Kaur G, Venketaraman V. Biology (Basel). 2025 Apr 13;14(4):417. doi: 10.3390/biology14040417.
- Recombinant Rv0222 protein from Mycobacterium tuberculosis regulates host Th9 differentiation function in vitro. Aizezi M, Wusiman A, Kuerban K, Aimaierjiang R, Tuohetaerbaike B, Guo B, Aimulajiang K. Microb Pathog. 2025 Apr 14:107593. doi: 10.1016/j.micpath.2025.107593. Epub ahead of print.
- Live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in adults with or without M tuberculosis sensitisation: a single-centre, phase 1b-2a, double-blind, dose-escalation, randomised controlled trial. Luabeya AKK, Rozot V, Imbratta C, Ratangee F, Shenje J, Tameris M, Mendelsohn SC, Geldenhuys H, Fisher M, Musvosvi M, Young C, Mulenga H, Bilek N, Mabwe S, Jelsbak IM, Rodríguez E, Puentes E, Doce J, Aguilo N, Martin C, Pillay C, Tait D, Russell M, Van Der Merve A, Rutkowski K, Hunt D, Ginsberg A, Scriba TJ, Hatherill M; A050 team. Lancet Glob Health. 2025 Apr 15:S2214-109X(25)00046-4. doi: 10.1016/S2214-109X(25)00046-4. Epub ahead of print.
- Scale-up of a low-temperature spray-drying process for a tuberculosis vaccine candidate using lab-scale equipment. Aisenstat M, McCollum J, Ordoubadi M, Wang H, Minootan Z, Gerhardt A, Martin AR, Fox CB, Vehring R. Int J Pharm. 2025 Apr 15;674:125456. doi: 10.1016/j.ijpharm.2025.125456. Epub 2025 Mar 10.
- Customized MHC Class I & II restricted peptides from clinical isolates of Mycobacterium tuberculosis tweak strong cellular immune response in Healthy individuals and Pulmonary Tuberculosis patients: A potential candidate in vaccine design. Sharma N, Joshi B, Sharma B, Kumar S, Mohanty KK, Prakash H. Tuberculosis (Edinb). 2025 Apr 15;152:102640. doi: 10.1016/j.tube.2025.102640. Epub ahead of print.
- Effect of Bacillus Calmette-Guérin vaccination against Mycobacterium tuberculosis infection in children: an updated systematic review and meta-analysis. Cai S, Luo Q, Zhou G, Guo X, Dong Y, Chen H, Luo S, He J, Xia Y, Li H, Zhou Y, Song C. Int J Infect Dis. 2025 Apr 16:107909. doi: 10.1016/j.ijid.2025.107909. Epub ahead of print.
- Bioinformatics analysis, immunogenicity, and therapeutic efficacy evaluation of a novel multi-stage, multi-epitope DNA vaccine for tuberculosis. Guo J, Jia Z, Yang Y, Wang N, Xue Y, Xiao L, Wang F, Wang L, Wang X, Liu Y, Wang J, Gong W, Zhao H, Liang Y, Wu X. Int Immunopharmacol. 2025 Apr 16;152:114415. doi: 10.1016/j.intimp.2025.114415. Epub 2025 Mar 13.
- Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices. Tengattini S, Bavaro T, Rinaldi F, Temporini C, Pollegioni L, Terreni M, Piubelli L. Vaccine. 2025 Apr 19;53:126932. doi: 10.1016/j.vaccine.2025.126932. Epub 2025 Mar 2.
- Heat-inactivated Mycobacterium bovis and P22PI protein immunocomplex: Two candidates for use as immunostimulants of innate immune response. Agulló-Ros I, Burucúa MM, Cheuquepán FA, Domínguez M, Sevilla IA, Martínez R, Plá N, Risalde MA, Marin MS. Vet Microbiol. 2025 Apr 21;305:110527. doi: 10.1016/j.vetmic.2025.110527. Epub ahead of print.
- Current advancements in nanoparticles for vaccines and drug delivery for the treatment of tuberculosis. Sharma DK. J Microbiol Methods. 2025 Apr 23;232-234:107138. doi: 10.1016/j.mimet.2025.107138. Epub ahead of print.
- Prediction of a novel synthetic peptide vaccine against tuberculosis and validation of its immunogenicity. Zhang D, Wang D, Jiang S, Wan Y, Zhao Y, Dong W, Li X, Fu L, Zhang W. Int Immunopharmacol. 2025 Apr 24;153:114531. doi: 10.1016/j.intimp.2025.114531. Epub 2025 Mar 27.
- Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvant. Larsen SE, Rais M, Reese VA, Ferede D, Pecor T, Kaur S, Nag D, Smytheman T, Gray SA, Carter D, Baldwin SL, Coler RN. Immunohorizons. 2025 Apr 26;9(6):vlaf014. doi: 10.1093/immhor/vlaf014.
- BCG vaccination decline and pediatric tuberculosis rise in Brazil: spatial-temporal study. Carvalho FR, Ramos-Silva A, Pires DC, Oliveira CVY, Cardoso CAA, Sant’Anna CC, Lima EC, Silva AA. Rev Saude Publica. 2025 Apr 28;59:e13. doi: 10.11606/s1518-8787.2025059006458.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D